SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 215.88 |
| Enterprise Value ($M) | 28.34 |
| Book Value ($M) | 552.95 |
| Book Value / Share | 11.96 |
| Price / Book | 0.39 |
| NCAV ($M) | 459.68 |
| NCAV / Share | 9.94 |
| Price / NCAV | 0.47 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.25 |
| Return on Assets (ROA) | -0.42 |
| Return on Equity (ROE) | -0.47 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 17.33 |
| Current Ratio | 17.33 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 510.76 |
| Assets | 604.03 |
| Liabilities | 51.08 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Deep Track Capital, LP | |||
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | |||
| 13G/A | Ra Capital Management, L.p. | |||
| 13G/A | Janus Henderson Group Plc | |||
| 13G/A | Biotechnology Value Fund L P | |||
| 13G/A | Goldman Sachs Group Inc | |||
| 13G/A | BlackRock, Inc. | 10.70 | 1.98 | |
| 13G/A | Viking Global Investors Lp | 0.00 | -100.00 | |
| 13G/A | Vanguard Group Inc | 5.32 | 0.00 | |
| 13G/A | Kirn David | 4.70 | 0.52 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 58,467 | 483,759 | 12.09 | |
| 50,136 | 343,968 | 14.58 | |
| 73,334 | 602,990 | 12.16 | |
| 109,847 | 511,896 | 21.46 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ERAS – Erasca, Inc. | EWTX – Edgewise Therapeutics, Inc. |
| EXEL – Exelixis, Inc. | FGEN – FibroGen, Inc. |
| GBIO – Generation Bio Co. |
Financial data and stock pages provided by
Fintel.io